TB Alliance and Lupin Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB
Agreement between non-profit product development partnership and multinational pharmaceutical company will expand access to new TB drug NEW YORK and
TB Alliance Convenes Community Engagement Stakeholders to Discuss Clinical Trial Updates
TB Alliance’s Community Engagement (CE) forums provide an opportunity for capacity building and for members of TB-affected communities to share
Building the Largest TB Drug Portfolio
TB Alliance has built the largest portfolio of potential new tuberculosis (TB) treatments in history. Since inception, it has introduced
Without Community, Research is Not Possible: Community Engagement in TB Research
When TB Alliance was formed, there had been no late-stage tuberculosis (TB) research trials conducted to modern standards. In addition
At United Nations High Level Meeting, World Leaders Commit to Ending TB
Unfortunately, the recent history of the tuberculosis (TB) pandemic has in large part been defined by neglect—inadequate funding for research
Launch of UNITE4TB partnership marks a new era in Tuberculosis treatment development
NEW YORK (July 15, 2021)—To advance anti-tuberculosis (TB) science and enable the progression of new, safe, and affordable treatment solutions
New Trial Results Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of Linezolid
TB Alliance’s ZeNix trial in South Africa and Eastern Europe sought to optimize the 6-month treatment regimen with reduced exposure
TB Alliance Welcomes Dr. Suvanand Sahu to the Access Advisory Committee
He will bring more than 20 years of global and country level experience in TB and a people-centered approach to
TB Alliance Congratulates Dr. Dan Everitt on Career Transition
After more than 40 years working in medicine, Dan Everitt, MD, is moving on from his role as Vice President
The First Clinical Trial of Multiple New TB Drugs in Combination
TB Alliance has shifted the TB treatment research paradigm from a focus on developing individual drugs to one of developing